N
Naveris
Delivers innovations in technology with the potential to transform cancer detection, drug development, and clinical trials
About Naveris
Naveris is a molecular diagnostics company that develops and commercializes novel blood and saliva tests for the early detection and clinical management of viral-associated cancers. Its flagship product, NavDx, is a blood test that can detect HPV-associated cancers, such as head and neck cancers, at an early stage.
The company's mission is to transform cancer detection, drug development, and clinical trials through its technological innovations. Naveris operates in the biotechnology and healthcare sectors, with a focus on oncology. Its primary clients are healthcare providers, including oncologists and surgeons, who use its diagnostic tools for patient care.
Naveris's business model is centered on the sale of its diagnostic tests. As a commercial-stage life sciences company, it generates revenue by providing these tests to the healthcare market. The company is also involved in drug development and clinical trials, which could represent additional revenue streams or future growth opportunities.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2017
- Headquarters
- Waltham, United States
- Employees
- 134
- Open positions
- 15
- Dealroom signal
- 91.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Apr 2026 | $160M | $160M | CareDx | ↗ |
| EARLY VCOther financing | Jul 2024 | $17M | $167M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Naveris is 14K monthly website visits, up 204.3% over the last three months. Naveris's team grew 20.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Gurnet Point Capital
Sky Ventures Group
BrightEdge
TECHU
Other known investors2 additional known investors
CareDx
UNC Health
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Naveris on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Naveris’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.